Pneumopathie interstitielle dans la polyarthrite rhumatoïde : nouvelles données génétiques et perspectives thérapeutiques [Rheumatoid arthritis-associated interstitial lung disease : new genetic data and therapeutic perspectives]
Fiche du document
6 mars 2019
- doi: 10.53738/REVMED.2019.15.641.0536
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2019.15.641.0536
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/30860324
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_3052243319A61
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Field guides Keys (Identification guides) Identification guides Legends and stories Novels Stories Pneumonie interstitielle Pneumopathie interstitielle Pneumonie chronique Sciences de la gestion Gestion, Sciences de la Sciences de gestion Techniques de gestion Direction Management Nouvelles (littérature) RécitsCiter ce document
F. Valerio et al., « Pneumopathie interstitielle dans la polyarthrite rhumatoïde : nouvelles données génétiques et perspectives thérapeutiques [Rheumatoid arthritis-associated interstitial lung disease : new genetic data and therapeutic perspectives] », Serveur académique Lausannois, ID : 10.53738/REVMED.2019.15.641.0536
Métriques
Partage / Export
Résumé
Diffuse interstitial lung disease (ILD) is one of the most frequent extra-articular manifestation of rheumatoid arthritis (RA) and is an important factor of morbidity and mortality. However, the physiopathological mechanisms underlying RA-associated ILD remain poorly understood, and disease management is difficult in the absence of effective treatments and international guidelines. The recent identification of genetic variants and mutations similar to those observed in idiopathic pulmonary fibrosis (IPF), a disease affecting exclusively the lung, provides new insights into the understanding of RA-associated ILD. Furthermore, new antifibrotic drugs approved for the treatment of IPF, including pirfenidone and nintedanib, could also prove to be effective for RA-associated ILD. Studies are ongoing to confirm this hypothesis.